Posted from: Monday, March 02, 2015 - 05:00 PM - Present

Lenvima Approved for Thyroid Cancer

U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).  Lenvima is manufactured by Eisai.

The recommended dose is 24mg (two 10mg and one 4mg capsule) once daily. Eisai plans on launching Lenvima within two weeks. It will be available through a limited network of specialty pharmacies.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Tuesday, September 19, 2017 - 09:23 AM.